Tagged with R

Austria Mogens Guldberg, general manager of Novo Nordisk Austria, the Danish global powerhouse focused on innovative diabetic treatments, provides a unique insight into the obstacles associated with launching innovative products in Austria as well as the revolution required in Austria’s diabetic approach. He also highlights how specifically Novo Nordisk assists in…

Japan Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within Japan and his mission to instill a start-up culture within the Japanese biopharmaceutical industry. “[My mission is] urging universities, biotech start-ups…

USA Helen Stimson, president of the Delaware BioScience Association, discusses Delaware’s attractive cost of living, legal system, interconnectivity, as well as the vital role that the life sciences play within the state. Ms. Stimson, after a distinguished career with Agilent Technologies, you became president of the Delaware BioScience Association just a…

Ukraine Alexander Boiko, general manager of Novo Nordisk Ukraine, provides insights into the recent progress and remaining room for improvement in Ukraine’s health capacity when it comes to preventing, diagnosing, and treating diabetes, as well as the company’s unique commitment to partner with the government at the moment an unprecedented set…

Indonesia Suryo Suwignjo, President Director at Philips Indonesia, highlights the strong commitment and contribution of Philips to the development of the Indonesian healthcare system and how medical education is a crucial element in bringing high quality care to Indonesian citizens. Mr. Suryo, you were appointed as President Director in April 2014.…

Ukraine Vladimir Tkachenko, general manager of AMAXA PHARMA, a UK-headquartered pharmaceutical company focused on life-threatening therapeutic areas such as oncology and neonatology in the CIS countries, provides insights into AMAXA’s market positioning in Ukraine and the region, as well as his strategic priorities to further propel the eye-catching development pace of…

Hong Kong Henry Yau, MD and Honorary Assistant Professor at the University of Hong Kong Clinical Trials Centre (HKU-CTC) discusses the center’s development, the diverse range of services it offers, and the clinical trials environment in Hong Kong. Having been with the organization since nearly the beginning from 2000, how have you…

Austria Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis of the vicious cycle associated with establishing generics market share in Austria as well as the inconsistences of government regulations…

Ukraine Mykola Gumenyuk, CEO of Yuria-Pharm, documents the strategy that has been driving the impressive growth of this ambitious company, how Yuria-Pharm has evolved into the leading manufacturer of solutions for infusions and hospital supplier in Ukraine and CIS, and how it plans to significantly increase its international activities in all…

USA Speaking exclusively to PharmaBoardroom at the 2017 BIO Convention in San Diego, former FDA Commissioner Andrew von Eschenbach lifts the lid on the ‘FDA Beyond Our Borders’ project that he initiated. Dr. von Eschenbach, you were the FDA Commissioner for three years, from 2006 to 2009. What do you see…

Indonesia Darodjatun Sanusi, Executive Director of GP Farmasi (National Association of Local Companies in Indonesia), explains the opportunities and challenges that his members are facing as well as the future directions that the industry should take to further enhance its capabilities and continue its growth. As Executive Director of GP Farmasi,…

Hong Kong Shawn, as I understand, SinoMab today is a clinical stage biopharma company focusing on the development of therapeutic monoclonal antibodies (mAbs) – hence the name. Can you tell us a little about the genesis of the company? Having previously studied and worked in the UK and US, I was asked…